| Bromfenac as Adjunctive Treatment with Intravitreal Bevacizumab in Branch Retinal Vein Occlusion of Macular Edema. |
|
Jong Myoung Yun, Young Wook Cho, Jong Won Moon |
|
Department of Ophthalmology, Daegu Fatima Hospital, Daegu, Korea. anantos@naver.com |
| 황반부종이 동반된 망막분지정맥폐쇄에서 베바시주맙 유리체내주사의 보조치료로써 브롬페낙의 효과 |
|
윤종명 · 조영욱 · 문종원 |
|
대구파티마병원 안과 |
Correspondence:
Jong Won Moon,
Email: anantos@naver.com
|
|
Received: 20 June 2019 • Revised: 14 October 2019 • Accepted: 17 January 2020 |
| Abstract |
PURPOSE
To evaluate the effectiveness of 0.1% topical bromfenac as an adjunctive treatment with intravitreal bevacizumab (IVB) injection for branch retinal vein occlusion (BRVO) patients. METHODS: We retrospectively evaluated 68 eyes of 68 patients with macular edema (ME) secondary to BRVO who were treated with IVB injection and followed up for at least 12 months. Of the 68 eyes, 38 were treated with IVB combined with 0.1% topical bromfenac and 30 were treated with IVB alone. IVB reinjection was performed in cases of recurrence. The primary outcome measurement was the number of IVB injections. Changes in the best-corrected visual acuity (BCVA) and central foveal thickness (CFT) during the 12-month follow-up were compared. RESULTS: There was no significant difference in the BCVA or CFT between the two groups at the initial and final examinations. However, the number of IVB injections was significantly lower in the 0.1% bromfenac-treated eyes (p < 0.01) than in the control eyes (4.1 ± 0.7 vs. 5.0 ± 0.6 times). CONCLUSIONS: Compared to IVB monotherapy, topical bromfenac as an adjunctive treatment with IVB injection of eyes with ME secondary to BRVO did not affect visual outcomes, but it reduced the number of IVB injections. |
| Key Words:
Bevacizumab;Branch retinal vein occlusion;Macular edema;Nonsteroidal anti-inflammatory drug (NSAIDs) |
PDF Links
Full text via DOI
Download Citation
